



Navicixizumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name

Navicixizumab

Accession Number

DB12634

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Description

Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

Protein chemical formula

Not Available



Sequences

Not Available

Synonyms

Not Available

External IDs [i](#)

OMP 305 B83 / OMP 305B83 / OMP-305B83

Categories

Not Available

UNII

[1W14T9L25W](#)

CAS number

1638338-43-8

PHARMACOLOGY

Indication

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available



Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs ⓘ

Not Available

INTERACTIONS

Drug Interactions ⓘ

Not Available



REFERENCES

General References

Not Available

External Links

PubChem Substance

[347911355](#)

CLINICAL TRIALS

Clinical Trials ⓘ

| PHASE | ↕ | STATUS | ↕ | PURPOSE | ↕ | CONDITIONS | ↕ | COUNT | ↕ |
|-------|---|------------|---|-----------|---|--|---|-------|---|
| 1 | | Completed | | Treatment | | Advanced Solid Tumor Malignancies | | 1 | |
| 1 | | Recruiting | | Treatment | | Cancer Ovaries / Cancer Peritoneal / Fallopian Tube Cancer | | 1 | |
| 1 | | Recruiting | | Treatment | | Metastatic Colorectal Cancers | | 1 | |

Showing 1 to 3 of 3 entries

< >

PHARMACOECONOMICS

Manufacturers

Not Available

Packagers

Not Available



Not Available

Patents

Not Available

PROPERTIES

State

Not Available

Experimental Properties

Not Available

TAXONOMY

Description

Not Available

Kingdom

Organic Compounds

Super Class

Organic Acids

Class

Carboxylic Acids and Derivatives

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent



Substituents

Not Available

Molecular Framework

Not Available

External Descriptors

Not Available

Drug created on October 20, 2016 17:21 / Updated on November 02, 2018 07:27

About

[About DrugBank](#)

[DrugBank Blog](#)

[Wishart Research Group](#)

[Terms of Use](#)

[Privacy Policy](#)

Support

[FAQ](#)

[Help](#)

[Email Support](#)

Commercial Products

[API Pricing](#)

[API Docs](#)

[Data Licenses](#)

[Support](#)



research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**

